Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Radiotherapy in Primary Mediastinal B-cell Lymphoma

Evaluating its effect on overall survival

Publish date:: February 17, 2016

There is a significant survival benefit associated with radiotherapy (RT) in patients receiving multi-agent chemotherapy in the rituximab era, according to a study of 465 patients with primary mediastinal B-cell lymphoma and a median age of 36 years. Researchers found:

43% of patients received RT.

5-year overall survival (OS) for the entire cohort was 87%, with the non-RT group at 83% and the RT group at 93%.

On univariate analysis, OS was improved with RT (HR=0.34).

On multivariate analysis, RT remained significantly associated with improved OS (HR=0.44) while Medicare insurance status and increasing stage remained significantly associated with OS decrement.

Propensity score matched analysis confirmed the OS benefit associated with RT.

Citation: Jackson MW, Rusthoven CG, Jones BL, Kamdar M, Rabinovitch R. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. [Published online ahead of print February 6, 2016]. Am J Hematol. doi: 10.1002/ajh.24325.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,